These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia. Ribera JM Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835 [TBL] [Abstract][Full Text] [Related]
3. CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy. Pillai V; Muralidharan K; Meng W; Bagashev A; Oldridge DA; Rosenthal J; Van Arnam J; Melenhorst JJ; Mohan D; DiNofia AM; Luo M; Cherian S; Fromm JR; Wertheim G; Thomas-Tikhonenko A; Paessler M; June CH; Luning Prak ET; Bhoj VG; Grupp SA; Maude SL; Rheingold SR Blood Adv; 2019 Nov; 3(22):3539-3549. PubMed ID: 31738832 [TBL] [Abstract][Full Text] [Related]
4. Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Viardot A; Locatelli F; Stieglmaier J; Zaman F; Jabbour E Ann Hematol; 2020 Oct; 99(10):2215-2229. PubMed ID: 32856140 [TBL] [Abstract][Full Text] [Related]
5. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Ruella M; Gill S Expert Opin Biol Ther; 2015 Jun; 15(6):761-6. PubMed ID: 25640460 [TBL] [Abstract][Full Text] [Related]
6. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633 [TBL] [Abstract][Full Text] [Related]
8. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia. Singh N; Frey NV; Grupp SA; Maude SL Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534 [TBL] [Abstract][Full Text] [Related]
9. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. DasGupta RK; Marini BL; Rudoni J; Perissinotti AJ J Oncol Pharm Pract; 2018 Sep; 24(6):453-467. PubMed ID: 28583018 [TBL] [Abstract][Full Text] [Related]
10. Clinical applications and safety evaluation of the new CD19 specific T-cell engager antibody construct blinatumomab. Wilke AC; Gökbuget N Expert Opin Drug Saf; 2017 Oct; 16(10):1191-1202. PubMed ID: 28825327 [TBL] [Abstract][Full Text] [Related]
11. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia. Le Jeune C; Thomas X Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176 [TBL] [Abstract][Full Text] [Related]
12. An analytical biomarker for treatment of patients with recurrent B-ALL after remission induced by infusion of anti-CD19 chimeric antigen receptor T (CAR-T) cells. Zhang Y; Zhang W; Dai H; Wang Y; Shi F; Wang C; Guo Y; Liu Y; Chen M; Feng K; Zhang Y; Liu C; Yang Q; Li S; Han W Sci China Life Sci; 2016 Apr; 59(4):379-85. PubMed ID: 27009300 [TBL] [Abstract][Full Text] [Related]
13. Treatment with anti CD19 chimeric antigen receptor T cells after antibody-based immunotherapy in adults with acute lymphoblastic leukemia. Danylesko I; Chowers G; Shouval R; Besser MJ; Jacoby E; Shimoni A; Nagler A; Avigdor A Curr Res Transl Med; 2020 Jan; 68(1):17-22. PubMed ID: 31882377 [TBL] [Abstract][Full Text] [Related]
14. High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients. Pan J; Yang JF; Deng BP; Zhao XJ; Zhang X; Lin YH; Wu YN; Deng ZL; Zhang YL; Liu SH; Wu T; Lu PH; Lu DP; Chang AH; Tong CR Leukemia; 2017 Dec; 31(12):2587-2593. PubMed ID: 28490811 [TBL] [Abstract][Full Text] [Related]
15. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Goebeler ME; Bargou R Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240 [TBL] [Abstract][Full Text] [Related]
16. Incorporating Immunotherapy Into the Treatment Strategies of B-Cell Adult Acute Lymphoblastic Leukemia: The Role of Blinatumomab and Inotuzumab Ozogamicin. Kantarjian H; Jabbour E Am Soc Clin Oncol Educ Book; 2018 May; 38():574-578. PubMed ID: 30231308 [TBL] [Abstract][Full Text] [Related]
17. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Klinger M; Brandl C; Zugmaier G; Hijazi Y; Bargou RC; Topp MS; Gökbuget N; Neumann S; Goebeler M; Viardot A; Stelljes M; Brüggemann M; Hoelzer D; Degenhard E; Nagorsen D; Baeuerle PA; Wolf A; Kufer P Blood; 2012 Jun; 119(26):6226-33. PubMed ID: 22592608 [TBL] [Abstract][Full Text] [Related]
18. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia. Lyons KU; Gore L Haematologica; 2024 Jun; 109(6):1668-1676. PubMed ID: 38832422 [TBL] [Abstract][Full Text] [Related]
19. How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated? Gökbuget N Best Pract Res Clin Haematol; 2017 Sep; 30(3):261-274. PubMed ID: 29050699 [TBL] [Abstract][Full Text] [Related]